Clinical trial
Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity…
NCT00346814 · Asociación para Evitar la Ceguera en México, Other · Recruiting
Key facts
| NCT number | NCT00346814 |
|---|---|
| Title | Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome |
| Official title | Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome |
| Lead sponsor | Asociación para Evitar la Ceguera en México, Other |
| Status | Recruiting |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Retinopathy of Prematurity |
| Intervention type | Drug |
| Interventions | intravitreal injection |
| Start date | Jul 1, 2007 |
| Primary completion | Jul 1, 2007 |
| Completion | Nov 1, 2024 |
| First posted | Jun 30, 2006 |
| Last update posted | Jul 31, 2024 |
| Countries | Mexico |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: